Professor Kenji Hirayama

 

Professor Kenji Hirayama

hirayama

Qualifications

  • MD, PhD

Personal/work Web page addresses

Research gate or Linked-in account links

Affiliation(s)

  • Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University

Background

  • 2001-: Professor, NEKKEN, Nagasaki University
  • 1995-2001:Professor, Saitama Medical University
  • 1989-92: Research Fellow, Harvard School of Public Health
  • 1985-89: Medical Institute of Bioregulation, Kyushu University
  • 1981-85: PhD course, Human Genetics, Medical Research Institute, Tokyo Medical and Dental University

Teaching

Current roles: Course Director of Health Innovation, Responsible for Immunology and Biotechnology courses

Teaching experience: Course Director of Master of Tropical Medicine, Nagasaki University Graduate school of Biomedical Science. Medical Parasitology, Clinical Immunology, Tropical Infectious diseases, Tropical Public Health, Research Ethics, Vaccinology, Clinical Product Development

Research

Vaccine development for malaria, Dengue, and Chagas Disease using DNA or recombinant vaccine. (Hisamitsu, Pasteur Paris, European Vaccine Initiative)

Drug development for malaria and trypanosomiasis using compound designing or herbal medicine. (Astellas, National Institute of Advanced Industrial Science and Technology, Institute of Natural Medicine Toyama University, Thammasat University)

HLA regulated Immune responsiveness against malaria, dengue, Chagas and Schistosomiasis. (Tokyo Med Dent University, Research Institute of Tropical Medicine, Philippines, Pasteur Institute Ho Chi Minh, Kenya Medical Research Institute)

http://www.tm.nagasaki-u.ac.jp/hiraken/english/index.html

The country/countries where you work currently

  • France
  • Germany
  • UK
  • Thailand
  • Vietnam
  • Myanmar
  • Philippines
  • Kenya
  • Bolivia
  • Paraguay
  • DRCongo

Five MOST IMPORTANT/INTERESTING recent publications

2016 Nhi DM, Huy NT, Ohyama K, Kimura D, Lan NT, Uchida L, Thuong NV, Nhon CT, Phuc le H, Mai NT, Mizukami S, Bao LQ, Doan NN, Binh NV, Quang LC, Karbwang J, Yui K, Morita K, Huong VT, Hirayama K. A Proteomic Approach Identifies Candidate Early Biomarkers to Predict Severe Dengue in Children. PLoS Negl Trop Dis. 2016 Feb 19;10(2):e0004435. doi: 10.1371/journal.pntd.0004435. eCollection 2016 Feb.
2015 Tanigawa C, Fujii Y, Miura M, Nzou SM, Mwangi AW, Nagi S, Hamano S, Njenga SM, Mbanefo EC, Hirayama K, Mwau M, Kaneko S. Species-Specific Serological Detection for Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. PLoS Negl Trop Dis. 2015 Aug 20;9(8):e0004021. doi: 10.1371/ journal. pntd.0004021. eCollection 2015 Aug.
2015 Mercado ES, Espino FE, Perez ML, Bilar JM, Bajaro JD, Huy NT, Baello BQ, Kikuchi M, Hirayama K. HLA-A*33:01 as protective allele for severe dengue in a population of Filipino children. PLoS One. 2015 Feb 6;10(2):e0115619. doi: 10.1371/journal.pone.0115619. eCollection 2015.
2014 Fujii Y, Kaneko S, Nzou SM, Mwau M, Njenga SM, Tanigawa C, Kimotho J, Mwangi AW, Kiche I, Matsumoto S, Niki M, Osada-Oka M, Ichinose Y, Inoue M, Itoh M, Tachibana H, Ishii K, Tsuboi T, Yoshida LM, Mondal D, Haque R, Hamano S, Changoma M, Hoshi T, Kamo K, Karama M, Miura M, Hirayama K. Serological surveillance development for tropical infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture models. PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3040. doi: 10.1371/journal.pntd.0003040. eCollection 2014.
2014 Cherif MS, Shuaibu MN, Kodama Y, Kurosaki T, Helegbe GK, Kikuchi M, Ichinose A, Yanagi T, Sasaki H, Yui K, Tien NH, Karbwang J, Hirayama K. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model. Vaccine. 2014 Apr 7;32(17):1998-2006. doi: 10.1016/j.vaccine.2014.01.005. Epub 2014 Jan 15.

Message

I am teaching Biotechnology, Immunology with Prof Yui and Research Ethics with Prof Juntra. My research area is immunology, human genetics and product development in tropical infectious diseases, and I am currently interested in research that contributes to the prevention and treatment of tropical infectious diseases with high morbidity and mortality. Production of vaccines and drugs has been my dream ever since I decided to be a doctor. I realized that such research should be pursued as a joint team gathering the forces of academia, public domains and private sectors, the so called PPP. For more than ten years, I have been involved in such projects for the control of malaria, dengue fever, Chagas disease and schistosomiasis. I hope you will be interested in our activity.

PAGETOP